OPTIONS OF INTERFERON-FREE THERAPY FOR HCV INFECTION. A CASE STUDY. COMPARISON OF NON-INVASIVE METHODS FOR LIVER FIBROSIS ASSESSMENT

Ya.E. Saranskaya, L. Kiseleva, L. Il'mukhina
{"title":"OPTIONS OF INTERFERON-FREE THERAPY FOR HCV INFECTION. A CASE STUDY. COMPARISON OF NON-INVASIVE METHODS FOR LIVER FIBROSIS ASSESSMENT","authors":"Ya.E. Saranskaya, L. Kiseleva, L. Il'mukhina","doi":"10.34014/2227-1848-2022-1-39-48","DOIUrl":null,"url":null,"abstract":"The incidence of hepatitis C virus infection in Russia is 2–3 %. In our country the socio-economic damage caused by the increase in the incidence of chronic hepatitis and its consequences, such as liver cirrhosis and hepatocarcinoma, is enormous. The goal of antiviral therapy for chronic hepatitis C is a sustained virological response, which is associated with a biochemical response and regression of hepatic tissue fibrosis, which leads to a decrease in the liver cirrhosis development. \nThe purpose of the study is to determine the efficacy of interferon-free therapy; to compare the efficacy of non-invasive methods for liver fibrosis diagnostics in chronic hepatitis C. \nMaterials and Methods. The study included 63 patients who underwent direct antiviral therapy (dasabuvir and ombitasvir + paritaprevir + ritonavir (3D-therapy)) in combination with ribavirin or without it, depending on the hepatitis C virus genotype and the stage of liver fibrosis. The stage of hepatic tissue fibrosis was assessed by non-invasive methods, namely, elastography and vibration-controlled transient elastometry using FibriScanCompact 530 (Echosens, France). Liver fibrosis biomarkers (AAR, APRI, Fib-4, Forns index) were calculated; MDA test was conducted. \nResults. 100 % efficacy of dasabuvir and ombitasvir + paritaprevir + ritonavir was confirmed for both 8- and 12-week therapy in comorbid patients with extrahepatic manifestations, patients who underwent interferon-based therapy, regardless of liver fibrosis stage and disease duration. \nThe article provides a comparative description of non-invasive methods for assessing liver fibrosis in patients with chronic hepatitis C: elastography, elastometry and serum fibrosis indices (APRI, AAR, FIB-4, MDA, Forns index). Indirect fibrosis markers are useful, because they allow to determine the late stages of liver fibrosis (F3-F4 on the METAVIR scale) with a very high degree of confidence.","PeriodicalId":177722,"journal":{"name":"Ulyanovsk Medico-biological Journal","volume":"131 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ulyanovsk Medico-biological Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34014/2227-1848-2022-1-39-48","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The incidence of hepatitis C virus infection in Russia is 2–3 %. In our country the socio-economic damage caused by the increase in the incidence of chronic hepatitis and its consequences, such as liver cirrhosis and hepatocarcinoma, is enormous. The goal of antiviral therapy for chronic hepatitis C is a sustained virological response, which is associated with a biochemical response and regression of hepatic tissue fibrosis, which leads to a decrease in the liver cirrhosis development. The purpose of the study is to determine the efficacy of interferon-free therapy; to compare the efficacy of non-invasive methods for liver fibrosis diagnostics in chronic hepatitis C. Materials and Methods. The study included 63 patients who underwent direct antiviral therapy (dasabuvir and ombitasvir + paritaprevir + ritonavir (3D-therapy)) in combination with ribavirin or without it, depending on the hepatitis C virus genotype and the stage of liver fibrosis. The stage of hepatic tissue fibrosis was assessed by non-invasive methods, namely, elastography and vibration-controlled transient elastometry using FibriScanCompact 530 (Echosens, France). Liver fibrosis biomarkers (AAR, APRI, Fib-4, Forns index) were calculated; MDA test was conducted. Results. 100 % efficacy of dasabuvir and ombitasvir + paritaprevir + ritonavir was confirmed for both 8- and 12-week therapy in comorbid patients with extrahepatic manifestations, patients who underwent interferon-based therapy, regardless of liver fibrosis stage and disease duration. The article provides a comparative description of non-invasive methods for assessing liver fibrosis in patients with chronic hepatitis C: elastography, elastometry and serum fibrosis indices (APRI, AAR, FIB-4, MDA, Forns index). Indirect fibrosis markers are useful, because they allow to determine the late stages of liver fibrosis (F3-F4 on the METAVIR scale) with a very high degree of confidence.
丙型肝炎病毒感染的无干扰素治疗方案。案例研究。非侵入性肝纤维化评估方法的比较
俄罗斯丙型肝炎病毒感染率为2 - 3%。在我国,慢性肝炎及其后果(如肝硬化和肝癌)发病率的增加所造成的社会经济损害是巨大的。慢性丙型肝炎抗病毒治疗的目标是持续的病毒学反应,这与生化反应和肝组织纤维化的消退有关,从而导致肝硬化发展的减少。该研究的目的是确定无干扰素治疗的疗效;比较非侵入性方法诊断慢性丙型肝炎肝纤维化的疗效。该研究包括63名患者,根据丙型肝炎病毒基因型和肝纤维化阶段,接受直接抗病毒治疗(达沙布韦和奥姆比他韦+帕利他韦+利托那韦(3d治疗))联合利巴韦林或不联合利巴韦林。采用非侵入性方法评估肝组织纤维化的分期,即使用FibriScanCompact 530 (Echosens, France)进行弹性成像和振动控制瞬时弹性测量。计算肝纤维化生物标志物(AAR、APRI、Fib-4、Forns指数);进行MDA检测。结果:无论肝纤维化分期和病程如何,达沙布韦和ombitasvir + paritaprevir +利托那韦在8周和12周的治疗中均有100%的疗效。本文比较介绍了评估慢性丙型肝炎患者肝纤维化的无创方法:弹性成像、弹性测量和血清纤维化指数(APRI、AAR、FIB-4、MDA、Forns指数)。间接纤维化标志物是有用的,因为它们可以以非常高的置信度确定肝纤维化的晚期(METAVIR分级为F3-F4)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信